Ac t i o n | 28 Jul 2026 00:00:00 ET │ 17 pages AstraZeneca PLC (AZN.L) Pipeline still looks full. Raising EPS 1-3% and TP to £178 CITI'S TAKE AZN's 2Q results looked solid to us, with the call a good reminder of the size and breadth of its pipeline, with 19 key Phase III readouts expected in 2027 and AZN flagging 12 assets with peak sales potential >$5bn and 5 with peak potential $3-5bn expected to have pivotal readouts by 2030 and drive growth beyond. In our view, this underscores its ability to absorb se ...

Flash | 27 Jul 2026 09:24:09 ET │ 12 pages US Pharmaceuticals and Biotechnology AstraZeneca 2Q26 EPS call readthrough: Raising the bar on convenience and differentiation +1-404-443-4701 geoffrey.meacham@citi.com Jarwei Fang +1-212-816-5127 jarwei.fang@citi.com Nishant Gandhi, Ph.D. +1-212-816-2513 nishant.gandhi@citi.com CITI'S TAKE AstraZeneca (covered by Graham Parry) reported 2Q26 revenue of $15.4B (-$39M vs. BBG cons) and adjusted diluted EPS of $2.63/sh (+$0.15/sh) while maintaining the full-year guida ...